

( (S (S-TPC-1 (NP-SBJ Rorer Group Inc.)
	      (VP will
		  (VP report
		      (SBAR that
			    (S (NP-SBJ third-quarter profit)
			       (VP rose
				   (NP-EXT (QP more than 15) %)
				   (PP-DIR from
					   (ADVP-TMP (NP a year)
						     earlier))
				   ,
				   (SBAR-ADV though
					     (S (NP-SBJ the gain)
						(VP is
						    (ADJP-PRD wholly due
							      (PP to
								  (NP asset sales))))))))))))
     ,
     (NP-SBJ (NP Robert Cawthorn)
	     ,
	     (NP (NP chairman)
		 ,
		 (NP president)
		 and
		 (NP chief executive officer))
	     ,)
     (VP said
	 (SBAR 0
	       (S *T*-1)))
     .))
( (S (NP-SBJ His projection)
     (VP indicates
         (NP (NP profit)
             (PP-TMP in
		     (NP the latest quarter))
             (PP of
		 (NP (NP (NP (QP more than $ 17.4 million) *U*)
			 , 
			 or
			 (NP (NP 55 cents)
			     (NP-ADV a share)))
		     ,
		     (PP compared
			 (PP with
			     (NP (NP (NP (QP $ 15.2 million) *U*)
				     , 
				     or
				     (NP (NP 48 cents)
					 (NP-ADV a share))
				     ,)
				 (ADVP-TMP (NP a year)
					   ago))))))))
     .))
( (S (NP-SBJ Mr. Cawthorn)
     (VP said
         (PP-LOC in
		 (NP an interview))
         (SBAR that
               (S (NP-SBJ sales)
                  (VP will
                      (VP show
                          (NP (NP an increase)
                              (PP from
                                  (ADVP-TMP (NP a year)
					    ago))
                              (PP of
				  ``
				  (NP (QP somewhat less than 10) %))))))))
     .
     ''))
( (S (PP-TMP Through
	     (NP (NP the first six months)
		 (PP of
		     (NP 1989))))
     ,
     (NP-SBJ sales)
     (VP had
         (VP grown
             (NP-EXT (QP about 12) %)
             (PP-DIR from
		     (NP the year-earlier period))))
     .))
( (S (NP-SBJ (NP Growth)
             (PP of
                 (NP 10 %)))
     (VP would
         (VP make
             (S (NP-SBJ (NP sales)
			(PP for
			    (NP the latest quarter)))
		(NP-PRD (NP (QP $ 269 million) *U*)
			,
			(PP compared
			    (PP with
				(NP (NP $ (QP 244.6 million) *U*)
				    (ADVP-TMP (NP a year)
					      ago))))))))
     .))
( (S (NP-SBJ Mr. Cawthorn)
     (VP said
         (SBAR 0
               (S (NP-SBJ (NP the profit growth)
                          (PP-TMP in
				  (NP the latest quarter)))
                  (VP was
                      (ADJP-PRD due
                                (PP to
                                    (NP (NP the sale)
                                        (PP of
                                            (NP two Rorer drugs)))))))))
     .))
( (S (NP-SBJ-1 (NP Asilone)
               ,
               (NP an antacid)
               ,)
     (VP was
         (VP sold
             (NP *-1)
             (PP-DTV to
		     (NP (NP Boots PLC)
			 ,
			 (NP-LOC London)))))
     .))
( (S (NP-SBJ-1 (NP Thrombinar)
               ,
               (NP (NP a drug)
                   (VP used
		       (NP-2 *) 
                       (S-CLR (NP-SBJ *-2)
			      (VP to
				  (VP stanch
				      (NP bleeding))))))
               ,)
     (VP was
         (VP sold
             (NP *-1)
             (PP-DTV to
		     (NP (NP Jones Medical Industries Inc.)
			 ,
			 (NP-LOC St. Louis)))))
     .))
( (S (NP-SBJ He)
     (VP said
         (SBAR 0
               (S (NP-SBJ Rorer)
                  (VP (VP sold
			  (NP the drugs)
			  (PP-CLR for 
				  ``
				  (NP nice prices)
				  ''))
		      and
		      (VP will
			  (VP record
			      (NP (NP a
				      combined , pretax
				      gain)
				  (PP-LOC on
					  (NP the sales))
				  (PP of
				      (NP (QP $ 20 million) *U*)))))))))
     .))
( (S (S-TPC-1 (SBAR-ADV As
			(S (NP-SBJ (NP the gain)
				   (PP from
				       (NP the sales)))
			   (VP indicates)))
	      ,
	      (NP-SBJ operating profit)
	      (VP was 
		  (PP-LOC-PRD ``
			      (ADVP significantly)
			      ''
			      below
			      (NP the year-earlier level))))
     ,
     (NP-SBJ Mr. Cawthorn)
     (VP said
	 (SBAR 0
	       (S *T*-1)))
     .))
( (S (NP-SBJ Rorer)
     (PP-TMP in
	     (NP July))
     (VP had
         (VP projected
             (NP (NP lower third-quarter operating profit)
                 but
                 (NP (NP higher profit)
                     (PP for
                         (NP (NP all)
                             (PP of
                                 (NP 1989))))))))
     .))
( (S (NP-SBJ He)
     (VP said
         (SBAR 0
               (S (NP-SBJ the company)
                  (VP is
                      (ADVP-TMP still)
                      (VP looking
                          (PP-CLR for
				  ``
				  (NP (NP a strong fourth quarter)
				      (PP-LOC in
					      (NP (NP all areas)
						  --
						  (NP (NP sales)
						      ,
						      (NP operating income)
						      and
						      (NP net income)))))))))))
     .
     ''))
( (S (NP-SBJ Mr. Cawthorn)
     (VP attributed
         (NP (NP the decline)
             (PP-LOC in
		     (NP third-quarter operating profit)))
         (PP-CLR (PP to
		     (NP (NP the stronger dollar)
			 ,
			 (SBAR (WHNP-2 which)
			       (S (NP-SBJ *T*-2)
				  (VP reduces
				      (NP (NP the value)
					  (PP of
					      (NP overseas profit))
					  (SBAR (WHADVP-4 when)
						(S (NP-SBJ-1 it)
						   (VP is
						       (VP translated
							   (NP *-1)
							   (PP-CLR into
								   (NP dollars))
							   (ADVP-TMP *T*-4)))))))))))
		 ;
		 (PP to
		     (NP (NP accelerated buying)
			 (PP of
			     (NP Rorer products))
			 (PP-TMP in
				 (NP the second quarter))
			 (PP-PRP because of
				 (NP a then-pending 
				     (NAC-TMP July 1) 
				     price increase))))
		 , 
		 and
		 (PP to
		     (NP (NP higher marketing expenses)
			 (PP for
			     (NP (NP (NP Rorer 's)
				     Maalox antacid)
				 ,
				 (SBAR (WHNP-3 (WHNP whose sales and market share)
					       (PP-LOC in
						       (NP the U.S.)))
				       (S (NP-SBJ *T*-3)
					  (VP had
					      (VP slipped
						  (PP-TMP in
							  (NP (NP the first half)
							      (PP of
								  (NP 1989))))))))))))))
     .))
( (S (NP-SBJ He)
     (VP said
         (SBAR 0
               (S (NP-SBJ-1 Rorer)
                  (VP opted
                      (S (NP-SBJ-2 *-1)
                         (VP to
                             (VP sell
                                 (NP Asilone
                                     and
                                     Thrombinar)
				 (S-PRP (NP-SBJ *-2)
					(VP to
					    (VP raise
						(NP (NP revenue)
						    (SBAR (WHNP-3 that)
							  (S (NP-SBJ *T*-3)
							     (VP would
								 (VP `` kick start ''
								     (NP (NP its increased marketing efforts)
									 (PP-LOC behind
										 (NP (NP Maalox)
										     , 
										     (ADVP-TMP still)
										     (NP its top-selling product)
										     (PP with
											 (NP (NP (QP about $ 215 million) *U*)
											     (PP-LOC in
												     (NP world-wide sales))
											     (PP-TMP in
												     (NP 1988))))))))))))))))))))))
     .))
( (S-1 ``
       (NP-SBJ We)
       (VP had
	   (VP underfunded
	       (NP Maalox)
	       (PP-TMP for
		       (NP a year))
	       (PRN ,
		    ''
		    (S (NP-SBJ he)
		       (VP said
			   (SBAR 0
				 (S *T*-1))))
		    ,)
	       (SBAR-PRP because
			 (S (NP-SBJ the company)
			    (VP was
				(VP concentrating
				    (PP-CLR on
					    (NP (NP research and development)
						and
						(S-NOM (NP-SBJ *)
						       (VP promoting
							   (NP other drugs)))))))))))
       .))
( (S (NP-SBJ He)
     (VP said
         (SBAR 0
               (S (NP-SBJ Rorer)
                  (VP will
                      (VP spend
                          (NP (NP (ADJP (QP $ 15 million to $ 20 million) *U*)
				  more)
			      (PP *ICH*-1))
			  (PP-CLR on
				  (NP (NP Maalox advertising and promotion)
				      (PP-TMP in
					      (NP (NP the second half)
						  (PP of
						      (NP 1989))))))
			  (PP-1 than
				(PP-TMP in
					(NP the year-earlier period))))))))
     .))
( (S (S-TPC-1 (NP-SBJ (NP A `` big chunk '')
		      (PP of
			  (NP that additional spending)))
	      (VP came
		  (PP-TMP in
			  (NP the third quarter))))
     ,
     (NP-SBJ he)
     (VP said
	 (SBAR 0
	       (S *T*-1)))
     .))
